Structural interactions of BWC0977 with Klebsiella pneumoniae topoisomerase IV and biochemical basis of its broad-spectrum activity

Antimicrobial resistance is a growing global health crisis driving the urgent need for effective broad-spectrum antibiotics. BWC0977 is a pyrazino-oxazinone based novel bacterial topoisomerase inhibitor (NBTI) currently in Phase 1 clinical trials and demonstrates potent activity against multidrug-resistant Gram-negative and Gram-positive bacteria. It targets both DNA gyrase and topoisomerase IV with balanced low-nanomolar potencies, showing remarkable superiority over ciprofloxacin and gepotidacin. We report the first 3.05 Å cocrystal structure of BWC0977 bound to Klebsiella pneumoniae topoisomerase IV, revealing its binding mode and interaction residues. The reduced inhibition of BWC0977 against purified gyrase enzymes carrying an individual mutation at these residues supports the relevance of these molecular interactions. Mutational analyses in Escherichia coli strains show that single target mutations in gyrA or parC do not confer resistance, while simultaneous mutations in both genes result in over 250-fold reduced susceptibility. The compound also demonstrates more than 5000-fold selectivity for bacterial over human topoisomerases and retains efficacy against fluoroquinolone and carbapenem-resistant clinical isolates. Together, these structural, biochemical, and microbiological insights elucidate BWC0977's broad-spectrum antibacterial activity and reduced vulnerability to resistance, establishing it as a promising next-generation antibiotic to address the global threat of antimicrobial resistance.

Authors

Institutions

Publication Details

Journal
Communications Biology
Published
2025-11-25
DOI
https://doi.org/10.1038/s42003-025-09055-y
Citations
1
Primary Topic
Cancer therapeutics and mechanisms
Type
article
Field-Weighted Citation Impact
0.81

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Structural interactions of BWC0977 with Klebsiella pneumoniae topoisomerase IV and biochemical basis of its broad-spectrum activity

Eiki Yamashita, Nagakumar Bharatham, Vasanthi Ramachandran, Satoshi Murakami et al.
1 citations
Communications Biology
Cancer therapeutics and mechanisms
0.81
article

Structural interactions of BWC0977 with Klebsiella pneumoniae topoisomerase IV and biochemical basis of its broad-spectrum activity

Eiki Yamashita, Nagakumar Bharatham, Vasanthi Ramachandran, Satoshi Murakami, Maho Aoki, Anirudh P. Shanbhag, Shahul Hameed P, V Balasubramanian, Radha Nandishaiah, Ui Okada, Nainesh Katagihallimath, Santanu Datta, Siddhartha P. Sarma, Sreevalli Sharma, Venkatesan Suryanarayanan, R. Jagadiswara Rao
article en
1 citations

Abstract

Antimicrobial resistance is a growing global health crisis driving the urgent need for effective broad-spectrum antibiotics. BWC0977 is a pyrazino-oxazinone based novel bacterial topoisomerase inhibitor (NBTI) currently in Phase 1 clinical trials and demonstrates potent activity against multidrug-resistant Gram-negative and Gram-positive bacteria. It targets both DNA gyrase and topoisomerase IV with balanced low-nanomolar potencies, showing remarkable superiority over ciprofloxacin and gepotidacin. We report the first 3.05 Å cocrystal structure of BWC0977 bound to Klebsiella pneumoniae topoisomerase IV, revealing its binding mode and interaction residues. The reduced inhibition of BWC0977 against purified gyrase enzymes carrying an individual mutation at these residues supports the relevance of these molecular interactions. Mutational analyses in Escherichia coli strains show that single target mutations in gyrA or parC do not confer resistance, while simultaneous mutations in both genes result in over 250-fold reduced susceptibility. The compound also demonstrates more than 5000-fold selectivity for bacterial over human topoisomerases and retains efficacy against fluoroquinolone and carbapenem-resistant clinical isolates. Together, these structural, biochemical, and microbiological insights elucidate BWC0977's broad-spectrum antibacterial activity and reduced vulnerability to resistance, establishing it as a promising next-generation antibiotic to address the global threat of antimicrobial resistance.

Communications BiologyVol. 8(1)
University of Trans-Disciplinary Health Sciences and Technology (IN), Cellworks Research (India) (IN), Life Science Institute (JP), Protein Research Foundation (JP)
U.S. Department of Health and Human Services, V Foundation for Cancer Research, Japan Agency for Medical Research and Development, Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator, Department of Biotechnology, Government of West Bengal, Biomedical Advanced Research and Development Authority, Japan Society for the Promotion of Science, Biotechnology Industry Research Assistance Council, Institute for Protein Research, Osaka University
Openalex Percentile: Top 21%
Cancer therapeutics and mechanisms
0.81
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.